[
  {
    "objectID": "quarto/resources.html",
    "href": "quarto/resources.html",
    "title": "Resources",
    "section": "",
    "text": "FDA Standard Safety Tables and Figures: Integrated Guide\nClick here to download.\n\n\n\nPast Talks & Presentations\n\nPHUSE EU Connect Presentation\n\nDate: November 6, 2023\nClick here to download the presentation slide deck.\n\n\n\nR/Pharma Online Workshop\n\nDate: October 20, 2023\nClick here to download the workshop slide deck."
  },
  {
    "objectID": "quarto/getting_started.html",
    "href": "quarto/getting_started.html",
    "title": "Getting Started",
    "section": "",
    "text": "Environment Setup and Package Installation\nEnvironment Setup\nPlease ensure that R version 3.6 or higher is installed on your computer. This is required to install the cardinal package and its dependencies. You can check your current version of R by running sessionInfo() within the R console.\nInstalling Package Dependencies\nThe cardinal package requires several packages available on CRAN.\nTo use the cardinal package, ensure you have these necessary package dependencies installed by running the following code:\n\nCodeif (!require(\"gtsummary\")) install.packages(\"gtsummary\")\nif (!require(\"cards\")) install.packages(\"cards\")\nif (!require(\"cardx\")) install.packages(\"cardx\")\nif (!require(\"formatters\")) install.packages(\"formatters\")\nif (!require(\"rtables\")) install.packages(\"rtables\")\nif (!require(\"rlistings\")) install.packages(\"rlistings\")\nif (!require(\"tern\")) install.packages(\"tern\")\n\n\nOptionally, to run the examples provided within the cardinal package and on this site you can also install the random CDISC data package, which contains example datasets, by running the following:\n\nCodeif (!require(\"random.cdisc.data\")) install.packages(\"random.cdisc.data\")\n\n\nFor more information on these packages, see the Additional Resources section below.\nInstalling the cardinal Package\nTo install the cardinal package, run the following line of code:\n\nCodeif (!require(\"cardinal\")) remotes::install_github(\"pharmaverse/cardinal\")\n\n\nLoading Data\nThe table functions provided by cardinal are designed to work with any datasets which adhere to CDISC standards. If you have access to CDISC data, load this into your R environment as usual to use when generating tables.\nIf you do not have access to CDISC data, or want to run the examples provided within the package, you can use the random.cdisc.data package to load a selection of datasets containing example synthetic randomized CDISC data. Datasets are stored in the package by name, prefixed by the letter \"c\" (for “cached”). For example, after loading the random.cdisc.data package you can access an ADSL dataset by running cadsl, or ADAE with cadae. This data is loaded in where necessary as part of the provided examples.\nTemplate Navigation\nA list of all templates currently available in cardinal is provided in the Template Catalog, with tables designed based on the FDA Standard Safety Tables and Figures: Integrated Guide.\nEach template provided is associated with a function available within the cardinal package, and contains 4 sections:\n\n\nSpec. Screenshot: This tab provides a screenshot of the given table coming from the FDA Standard Safety Table and Figures document.\n\n\n\n\n\n\n\nTable: This tab displays the output table corresponding to the screenshot in the previous tab, generated using the associated cardinal table function. You can expect a similar output table when using the table function with your own data, depending on pre-processing and the customizations that you apply via the table function parameters.\n\n\n\n\n\n\n\nTable Setup: This tab provides the code used to generate the example table displayed in the previous tab, including the loading of necessary libraries and example datasets, and any pre-processing steps applied prior to generating the table.\n\n\n\n\n\n\n\nFunction Details: This tab includes details on the table-generating function used for this template. Table functions use the naming convention make_table_XX() where XX is the table number taken from the FDA Standard Safety Table and Figures document (preceded by a 0 if the number is a single digit). Any required variables for the input datasets are listed along with a description of all function arguments. This information is mirrored by the function’s help page accessible within R (i.e. ?make_table_XX). By default, all table generating functions use the {gtsummary} package - though we do support rtables functionality. To specify the use of which table engine is being used, engine specific functions can be called (make_table_02_rtables, for example).\n\n\n\n\n\n          A link to the function’s source code can be found at the bottom of the page in this tab:\n\n\n\n\nCreating Tables\nThere are many table-generating functions available within the cardinal package, each of which is used to generate a different FDA standard safety table using R. These functions create rtables table objects which can then be further customized, paginated, etc. if required using functions from the rtables package.\nUsing the Table Functions\nTo use the table functions you will need to load the cardinal package and then call the appropriate table function. For example, to create FDA Safety Table 2, you can run the following code:\n\nCodelibrary(dplyr)\nlibrary(cardinal)\n\n# Data pre-processing - ensure all necessary variables are present in the data\nadsl &lt;- random.cdisc.data::cadsl %&gt;%\n  mutate(AGEGR1 = as.factor(case_when(\n    AGE &gt;= 17 & AGE &lt; 65 ~ \"&gt;=17 to &lt;65\",\n    AGE &gt;= 65 ~ \"&gt;=65\",\n    AGE &gt;= 65 & AGE &lt; 75 ~ \"&gt;=65 to &lt;75\",\n    AGE &gt;= 75 ~ \"&gt;=75\"\n  )))\n\n# Create table\ntbl &lt;- make_table_02(df = adsl)\ntbl\n\n$table\n&lt;div id=\"lrcqfnotmk\" style=\"padding-left:0px;padding-right:0px;padding-top:10px;padding-bottom:10px;overflow-x:auto;overflow-y:auto;width:auto;height:auto;\"&gt;\n  &lt;style&gt;#lrcqfnotmk table {\n  font-family: system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji';\n  -webkit-font-smoothing: antialiased;\n  -moz-osx-font-smoothing: grayscale;\n}\n\n#lrcqfnotmk thead, #lrcqfnotmk tbody, #lrcqfnotmk tfoot, #lrcqfnotmk tr, #lrcqfnotmk td, #lrcqfnotmk th {\n  border-style: none;\n}\n\n#lrcqfnotmk p {\n  margin: 0;\n  padding: 0;\n}\n\n#lrcqfnotmk .gt_table {\n  display: table;\n  border-collapse: collapse;\n  line-height: normal;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #FFFFFF;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#lrcqfnotmk .gt_caption {\n  padding-top: 4px;\n  padding-bottom: 4px;\n}\n\n#lrcqfnotmk .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-color: #FFFFFF;\n  border-bottom-width: 0;\n}\n\n#lrcqfnotmk .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 3px;\n  padding-bottom: 5px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-color: #FFFFFF;\n  border-top-width: 0;\n}\n\n#lrcqfnotmk .gt_heading {\n  background-color: #FFFFFF;\n  text-align: center;\n  border-bottom-color: #FFFFFF;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#lrcqfnotmk .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#lrcqfnotmk .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#lrcqfnotmk .gt_col_heading {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#lrcqfnotmk .gt_column_spanner_outer {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#lrcqfnotmk .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#lrcqfnotmk .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#lrcqfnotmk .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 5px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#lrcqfnotmk .gt_spanner_row {\n  border-bottom-style: hidden;\n}\n\n#lrcqfnotmk .gt_group_heading {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  text-align: left;\n}\n\n#lrcqfnotmk .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#lrcqfnotmk .gt_from_md &gt; :first-child {\n  margin-top: 0;\n}\n\n#lrcqfnotmk .gt_from_md &gt; :last-child {\n  margin-bottom: 0;\n}\n\n#lrcqfnotmk .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#lrcqfnotmk .gt_stub {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#lrcqfnotmk .gt_stub_row_group {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 5px;\n  padding-right: 5px;\n  vertical-align: top;\n}\n\n#lrcqfnotmk .gt_row_group_first td {\n  border-top-width: 2px;\n}\n\n#lrcqfnotmk .gt_row_group_first th {\n  border-top-width: 2px;\n}\n\n#lrcqfnotmk .gt_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#lrcqfnotmk .gt_first_summary_row {\n  border-top-style: solid;\n  border-top-color: #D3D3D3;\n}\n\n#lrcqfnotmk .gt_first_summary_row.thick {\n  border-top-width: 2px;\n}\n\n#lrcqfnotmk .gt_last_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#lrcqfnotmk .gt_grand_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#lrcqfnotmk .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#lrcqfnotmk .gt_last_grand_summary_row_top {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-bottom-style: double;\n  border-bottom-width: 6px;\n  border-bottom-color: #D3D3D3;\n}\n\n#lrcqfnotmk .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#lrcqfnotmk .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#lrcqfnotmk .gt_footnotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#lrcqfnotmk .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#lrcqfnotmk .gt_sourcenotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#lrcqfnotmk .gt_sourcenote {\n  font-size: 90%;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#lrcqfnotmk .gt_left {\n  text-align: left;\n}\n\n#lrcqfnotmk .gt_center {\n  text-align: center;\n}\n\n#lrcqfnotmk .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#lrcqfnotmk .gt_font_normal {\n  font-weight: normal;\n}\n\n#lrcqfnotmk .gt_font_bold {\n  font-weight: bold;\n}\n\n#lrcqfnotmk .gt_font_italic {\n  font-style: italic;\n}\n\n#lrcqfnotmk .gt_super {\n  font-size: 65%;\n}\n\n#lrcqfnotmk .gt_footnote_marks {\n  font-size: 75%;\n  vertical-align: 0.4em;\n  position: initial;\n}\n\n#lrcqfnotmk .gt_asterisk {\n  font-size: 100%;\n  vertical-align: 0;\n}\n\n#lrcqfnotmk .gt_indent_1 {\n  text-indent: 5px;\n}\n\n#lrcqfnotmk .gt_indent_2 {\n  text-indent: 10px;\n}\n\n#lrcqfnotmk .gt_indent_3 {\n  text-indent: 15px;\n}\n\n#lrcqfnotmk .gt_indent_4 {\n  text-indent: 20px;\n}\n\n#lrcqfnotmk .gt_indent_5 {\n  text-indent: 25px;\n}\n\n#lrcqfnotmk .katex-display {\n  display: inline-flex !important;\n  margin-bottom: 0.75em !important;\n}\n\n#lrcqfnotmk div.Reactable &gt; div.rt-table &gt; div.rt-thead &gt; div.rt-tr.rt-tr-group-header &gt; div.rt-th-group:after {\n  height: 0px !important;\n}\n&lt;/style&gt;\n  &lt;table class=\"gt_table\" data-quarto-disable-processing=\"false\" data-quarto-bootstrap=\"false\"&gt;\n  &lt;thead&gt;\n    &lt;tr class=\"gt_col_headings\"&gt;\n      &lt;th class=\"gt_col_heading gt_columns_bottom_border gt_left\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"label\"&gt;&lt;span data-qmd-base64=\"KipDaGFyYWN0ZXJpc3RpYyoq\"&gt;&lt;span class='gt_from_md'&gt;&lt;strong&gt;Characteristic&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/th&gt;\n      &lt;th class=\"gt_col_heading gt_columns_bottom_border gt_right\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"stat_1\"&gt;&lt;span data-qmd-base64=\"KipBOiBEcnVnIFgqKiAgCk4gPSAxMzQ=\"&gt;&lt;span class='gt_from_md'&gt;&lt;strong&gt;A: Drug X&lt;/strong&gt;&lt;br /&gt;\nN = 134&lt;/span&gt;&lt;/span&gt;&lt;/th&gt;\n      &lt;th class=\"gt_col_heading gt_columns_bottom_border gt_right\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"stat_2\"&gt;&lt;span data-qmd-base64=\"KipCOiBQbGFjZWJvKiogIApOID0gMTM0\"&gt;&lt;span class='gt_from_md'&gt;&lt;strong&gt;B: Placebo&lt;/strong&gt;&lt;br /&gt;\nN = 134&lt;/span&gt;&lt;/span&gt;&lt;/th&gt;\n      &lt;th class=\"gt_col_heading gt_columns_bottom_border gt_right\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"stat_3\"&gt;&lt;span data-qmd-base64=\"KipDOiBDb21iaW5hdGlvbioqICAKTiA9IDEzMg==\"&gt;&lt;span class='gt_from_md'&gt;&lt;strong&gt;C: Combination&lt;/strong&gt;&lt;br /&gt;\nN = 132&lt;/span&gt;&lt;/span&gt;&lt;/th&gt;\n      &lt;th class=\"gt_col_heading gt_columns_bottom_border gt_right\" rowspan=\"1\" colspan=\"1\" scope=\"col\" id=\"stat_0\"&gt;&lt;span data-qmd-base64=\"KipUb3RhbCBQb3B1bGF0aW9uKiogIApOID0gNDAw\"&gt;&lt;span class='gt_from_md'&gt;&lt;strong&gt;Total Population&lt;/strong&gt;&lt;br /&gt;\nN = 400&lt;/span&gt;&lt;/span&gt;&lt;/th&gt;\n    &lt;/tr&gt;\n  &lt;/thead&gt;\n  &lt;tbody class=\"gt_table_body\"&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\" style=\"font-weight: bold;\"&gt;Sex, n (%)&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    F&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;79 (59%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;82 (61%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;70 (53%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;231 (58%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    M&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;55 (41%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;52 (39%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;62 (47%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;169 (42%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\" style=\"font-weight: bold;\"&gt;Age&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    Mean (SD)&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;33.77 (6.55)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;35.43 (7.90)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;35.43 (7.72)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;34.88 (7.44)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    Median (min - max)&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;33.00 (21.00 - 50.00)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;35.00 (21.00 - 62.00)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;35.00 (20.00 - 69.00)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;34.00 (20.00 - 69.00)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\" style=\"font-weight: bold;\"&gt;AGEGR1, n (%)&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    &gt;=17 to &lt;65&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;134 (100%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;134 (100%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;131 (99%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;399 (100%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    &gt;=65&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;1 (0.8%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;1 (0.3%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\" style=\"font-weight: bold;\"&gt;Race, n (%)&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    ASIAN&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;68 (51%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;67 (50%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;73 (55%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;208 (52%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    BLACK OR AFRICAN AMERICAN&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;31 (23%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;28 (21%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;32 (24%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;91 (23%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    WHITE&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;27 (20%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;26 (19%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;21 (16%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;74 (19%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    AMERICAN INDIAN OR ALASKA NATIVE&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;8 (6.0%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;11 (8.2%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;6 (4.5%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;25 (6.3%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    MULTIPLE&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;1 (0.7%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;1 (0.3%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;1 (0.7%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;1 (0.3%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    OTHER&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    UNKNOWN&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\" style=\"font-weight: bold;\"&gt;Ethnicity, n (%)&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    HISPANIC OR LATINO&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;15 (11%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;18 (13%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;15 (11%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;48 (12%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    NOT HISPANIC OR LATINO&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;104 (78%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;103 (77%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;101 (77%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;308 (77%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    NOT REPORTED&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;6 (4.5%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;10 (7.5%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;11 (8.3%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;27 (6.8%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    UNKNOWN&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;9 (6.7%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;3 (2.2%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;5 (3.8%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;17 (4.3%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\" style=\"font-weight: bold;\"&gt;Country, n (%)&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;&lt;br /&gt;&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    CHN&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;74 (55%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;81 (60%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;64 (48%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;219 (55%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    USA&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;10 (7.5%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;13 (9.7%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;17 (13%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;40 (10%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    BRA&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;13 (9.7%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;7 (5.2%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;10 (7.6%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;30 (7.5%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    PAK&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;12 (9.0%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;9 (6.7%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;10 (7.6%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;31 (7.8%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    NGA&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;8 (6.0%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;7 (5.2%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;11 (8.3%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;26 (6.5%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    RUS&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;5 (3.7%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;8 (6.0%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;6 (4.5%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;19 (4.8%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    JPN&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;5 (3.7%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;4 (3.0%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;9 (6.8%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;18 (4.5%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    GBR&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;4 (3.0%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;3 (2.2%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;2 (1.5%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;9 (2.3%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    CAN&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;3 (2.2%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;2 (1.5%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;3 (2.3%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;8 (2.0%)&lt;/td&gt;&lt;/tr&gt;\n    &lt;tr&gt;&lt;td headers=\"label\" class=\"gt_row gt_left\"&gt;    CHE&lt;/td&gt;\n&lt;td headers=\"stat_1\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_2\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_3\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;\n&lt;td headers=\"stat_0\" class=\"gt_row gt_right\"&gt;0 (0%)&lt;/td&gt;&lt;/tr&gt;\n  &lt;/tbody&gt;\n  \n  \n&lt;/table&gt;\n&lt;/div&gt;\n\n$ard\n$ard$tbl_summary\n   group1 group1_level variable variable_level stat_name stat_label stat\n1     ARM    A: Drug X      SEX              F         n          n   79\n2     ARM    A: Drug X      SEX              F         N          N  134\n3     ARM    A: Drug X      SEX              F         p          % 0.59\n4     ARM    A: Drug X      SEX              M         n          n   55\n5     ARM    A: Drug X      SEX              M         N          N  134\n6     ARM    A: Drug X      SEX              M         p          % 0.41\n7     ARM    A: Drug X   AGEGR1      &gt;=17 to …         n          n  134\n8     ARM    A: Drug X   AGEGR1      &gt;=17 to …         N          N  134\n9     ARM    A: Drug X   AGEGR1      &gt;=17 to …         p          %    1\n10    ARM    A: Drug X   AGEGR1           &gt;=65         n          n    0\n\n$ard$add_overall\n   variable variable_level   context stat_name stat_label  stat\n1       SEX              F categori…         n          n   231\n2       SEX              F categori…         N          N   400\n3       SEX              F categori…         p          % 0.578\n4       SEX              M categori…         n          n   169\n5       SEX              M categori…         N          N   400\n6       SEX              M categori…         p          % 0.423\n7    AGEGR1      &gt;=17 to … categori…         n          n   399\n8    AGEGR1      &gt;=17 to … categori…         N          N   400\n9    AGEGR1      &gt;=17 to … categori…         p          % 0.998\n10   AGEGR1           &gt;=65 categori…         n          n     1\n\n\nThe above table is created using the default settings. You can customize tables by specifying function parameter values to set input data, variables to include in the table, table annotations, etc.\nTable Customization\nEach template takes several arguments that can be set to generate a table that meets your requirements. A brief overview of the parameters for each template is provided in the Function Details section of each table template page (see the Function Details section above) and the function’s help page within R (i.e. ?make_table_XX), with many of these parameters being standard across table functions.\nTo customize the output table, you can modify the values of these arguments as per your requirements. For example, table 2 can be customized as follows:\n\nCodeadvs &lt;- random.cdisc.data::cadvs %&gt;%\n  filter(AVISIT == \"BASELINE\", VSTESTCD == \"TEMP\") %&gt;%\n  select(\"USUBJID\", \"AVAL\")\n\nanl &lt;- left_join(adsl, advs, by = \"USUBJID\") %&gt;% tern::df_explicit_na()\n\ntbl &lt;- make_table_02(\n  df = anl,\n  vars = c(\"SEX\", \"AGE\", \"RACE\", \"COUNTRY\", \"AVAL\")\n)\ntbl$tbl\n\nNULL\n\n\nNote that the prune_0 argument can be set to specify whether all-zero rows should be included in a table. For example, see that the demographics table below includes rows for OTHER and UNKNOWN for which all values are zero, whereas these two rows were excluded from the previous tables (prune_0 defaults to TRUE in make_table_02()).\n\nCodemake_table_02_rtables(df = anl, vars = \"RACE\", prune_0 = FALSE)\n\n                                              A: Drug X    B: Placebo   C: Combination   Total Population\nCharacteristic                                 (N=134)      (N=134)        (N=132)           (N=400)     \n—————————————————————————————————————————————————————————————————————————————————————————————————————————\nRace                                                                                                     \n  ASIAN                                       68 (50.7%)    67 (50%)      73 (55.3%)        208 (52%)    \n  BLACK OR AFRICAN AMERICAN                   31 (23.1%)   28 (20.9%)     32 (24.2%)        91 (22.8%)   \n  WHITE                                       27 (20.1%)   26 (19.4%)     21 (15.9%)        74 (18.5%)   \n  AMERICAN INDIAN OR ALASKA NATIVE              8 (6%)     11 (8.2%)       6 (4.5%)         25 (6.2%)    \n  MULTIPLE                                        0         1 (0.7%)          0              1 (0.2%)    \n  NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER       0         1 (0.7%)          0              1 (0.2%)    \n  OTHER                                           0            0              0                 0        \n  UNKNOWN                                         0            0              0                 0        \n\n\nFeature Requests\nIf you would like to request the addition of a new feature to a pre-existing function within cardinal, or would like a specific table template to be added, please file an issue on GitHub here or reach out to the cardinal team directly via our Slack channel here.\nYou can access the source code for all currently available functions in the cardinal GitHub repository here.\nAdditional Resources\nSee the following packages used by cardinal for more information:\n\n\ntern: Clinical trials analysis functions\n\nrtables: Table creation\n\nrlistings: Listing creation\n\nformatters: Additional rendering formatting\n\nrandom.cdisc.data: Example synthetic randomized CDISC datasets (required for examples only)"
  },
  {
    "objectID": "quarto/catalog/fda-table_12/index.html",
    "href": "quarto/catalog/fda-table_12/index.html",
    "title": "FDA Table 12",
    "section": "",
    "text": "Table Preview\nSetup\nBuild ARD\nBuild Table\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCode# Load libraries & data -------------------------------------\nlibrary(dplyr)\nlibrary(cards)\nlibrary(gtsummary)\n\nadsl &lt;- random.cdisc.data::cadsl\nadae &lt;- random.cdisc.data::cadae\nadae$DCSREAS[is.na(adae$DCSREAS)] &lt;- \"ADVERSE EVENT\"\n\n# Pre-processing --------------------------------------------\ndata &lt;- adae %&gt;%\n  filter(\n    # safety population\n    SAFFL == \"Y\",\n    # discontinuation due to AE\n    DCSREAS == \"ADVERSE EVENT\"\n  )\n\n\n\n\n\nCodeard &lt;- ard_stack_hierarchical(\n  data,\n  variables = c(AEBODSYS, AEDECOD),\n  by = TRT01A,\n  denominator = adsl,\n  id = USUBJID\n)\n\nard\n\n\n\n\n{cards} data frame: 162 x 13\n\n\n   group1 group1_level   group2 group2_level variable variable_level   context stat_name stat_label  stat fmt_fn warning error\n1    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      A: Drug X categori…         n          n   134      0              \n2    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      A: Drug X categori…         N          N   400      0              \n3    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      A: Drug X categori…         p          % 0.335   &lt;fn&gt;              \n4    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      B: Place… categori…         n          n   134      0              \n5    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      B: Place… categori…         N          N   400      0              \n6    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      B: Place… categori…         p          % 0.335   &lt;fn&gt;              \n7    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      C: Combi… categori…         n          n   132      0              \n8    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      C: Combi… categori…         N          N   400      0              \n9    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      C: Combi… categori…         p          %  0.33   &lt;fn&gt;              \n10 TRT01A    A: Drug X     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         n          n    53      0              \n11 TRT01A    A: Drug X     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         N          N   134      0              \n12 TRT01A    A: Drug X     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         p          % 0.396   &lt;fn&gt;              \n13 TRT01A    B: Place…     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         n          n    55      0              \n14 TRT01A    B: Place…     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         N          N   134      0              \n15 TRT01A    B: Place…     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         p          %  0.41   &lt;fn&gt;              \n16 TRT01A    C: Combi…     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         n          n    69      0              \n17 TRT01A    C: Combi…     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         N          N   132      0              \n18 TRT01A    C: Combi…     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         p          % 0.523   &lt;fn&gt;              \n19 TRT01A    A: Drug X AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         n          n    37      0              \n20 TRT01A    A: Drug X AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         N          N   134      0              \n21 TRT01A    A: Drug X AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         p          % 0.276   &lt;fn&gt;              \n22 TRT01A    B: Place… AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         n          n    37      0              \n23 TRT01A    B: Place… AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         N          N   134      0              \n24 TRT01A    B: Place… AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         p          % 0.276   &lt;fn&gt;              \n25 TRT01A    C: Combi… AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         n          n    50      0              \n26 TRT01A    C: Combi… AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         N          N   132      0              \n27 TRT01A    C: Combi… AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         p          % 0.379   &lt;fn&gt;              \n28 TRT01A    A: Drug X AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         n          n    33      0              \n29 TRT01A    A: Drug X AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         N          N   134      0              \n30 TRT01A    A: Drug X AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         p          % 0.246   &lt;fn&gt;              \n31 TRT01A    B: Place… AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         n          n    31      0              \n32 TRT01A    B: Place… AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         N          N   134      0              \n33 TRT01A    B: Place… AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         p          % 0.231   &lt;fn&gt;              \n34 TRT01A    C: Combi… AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         n          n    40      0              \n35 TRT01A    C: Combi… AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         N          N   132      0              \n36 TRT01A    C: Combi… AEBODSYS       cl A.1  AEDECOD      dcd A.1.… hierarch…         p          % 0.303   &lt;fn&gt;              \n37 TRT01A    A: Drug X     &lt;NA&gt;              AEBODSYS         cl B.1 hierarch…         n          n    35      0              \n38 TRT01A    A: Drug X     &lt;NA&gt;              AEBODSYS         cl B.1 hierarch…         N          N   134      0              \n39 TRT01A    A: Drug X     &lt;NA&gt;              AEBODSYS         cl B.1 hierarch…         p          % 0.261   &lt;fn&gt;              \n40 TRT01A    B: Place…     &lt;NA&gt;              AEBODSYS         cl B.1 hierarch…         n          n    41      0              \n\n\nℹ 122 more rows\n\n\nℹ Use `print(n = ...)` to see more rows\n\n\n\n\n\nCodetbl &lt;- tbl_hierarchical(\n  data,\n  variables = c(AEBODSYS, AEDECOD),\n  by = TRT01A,\n  id = USUBJID,\n  denominator = adsl,\n  overall_row = TRUE,\n  label = list(..ard_hierarchical_overall.. = \"Patients with at least one AE leading to discontinuation\")\n)\n\ntbl"
  },
  {
    "objectID": "quarto/about.html",
    "href": "quarto/about.html",
    "title": "About the Project",
    "section": "",
    "text": "The cardinal project (previously “falcon”) is a product of industry collaboration to encourage the development of shared code, expertise, knowledge, and products.\nIn the near future, the goal is to develop functionality to create regulatory reporting tables suitable for FDA filing. The long-term objective of this collaboration is to develop an R package that can be used industry wide - developing a cross-industry standard and reducing manual work from a reporting perspective."
  },
  {
    "objectID": "quarto/about.html#our-collaboration-journey",
    "href": "quarto/about.html#our-collaboration-journey",
    "title": "About the Project",
    "section": "Our Collaboration Journey",
    "text": "Our Collaboration Journey\nCurrent collaborators are from Roche, Sanofi, Boehringer Ingelheim, and Moderna. Developers are connected via Slack and GitHub for the creation of shared solutions using publicly available analysis packages for R. Developers are invited to browse the cardinal project repository and related packages for insight into our template designs.\n\nJoining as a Collaborator\nAs always we invite further collaboration and welcome additional companies to join the cardinal initiative and contribute to the project. Please feel free to contact any of the repository maintainers for more information and check out the section below for more information on joining the project as a developer.\n\nInformation for Developers\nAs a pharmaverse collaboration, we invite any interested developers to join the cardinal team and contribute to template development. To onboard as a developer, please reach out to one of the cardinal Product Owners (Vincent Shen, Freeman Wang, Kavitha Allala, Lian Lin) to receive access to the cardinal GitHub repository.\nTasks are assigned and prioritized via issues on our GitHub project board and worked on in development branches. Members of the team will review each other’s code and make suggestions before new functions and features are incorporated into the package.\nWe encourage onboarding developers to familiarize themselves with the following packages as they contain functions leveraged by cardinal for table creation:\n\ngtsummary: Table creation\ncards: Analysis Results Dataset creation\ncardx: Extended ARD creation functions"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "cardinal",
    "section": "",
    "text": "Warning\n\n\n\nPlease note that the cardinal project is currently undergoing major structural changes and is subject to change without notice.\nSome informational pages may show outdated information while the restructuring is in progress.\n\n\n\n\n\nImplementation of FDA Safety Tables and Figures\n\n\n\n\n\n\n\n\n\nWhat is cardinal?\nThe cardinal initiative (formerly “falcon”) is an industry collaborative effort under pharmaverse that brings together pharmaceutical companies with the aspiration of building and open-sourcing a catalog of harmonized tables, listings, and graphs (TLGs) in clinical study reporting. Leveraging existing open-source R packages, cardinal aims to simplify the process of output review, comparison, and meta-analyses, fostering efficient communication among stakeholders in the pharmaceutical sector while aligning with CDISC’s ARD/ARM effort at the same time. Drawing inspiration from the FDA Standard Safety Tables and Figures Integrated Guide, we develop open-source templates. Future plans entail expanding the catalog of templates through continuous collaboration from participating companies and inviting wider industry to promote harmonization of TLGs for clinical reporting.\n\nGetting Started\nTemplate Catalog \n \n\n\nOur Collaboration Journey\nFAQ\n\nUpcoming Talks & Presentations\nNo upcoming talks or presentations currently scheduled. Stay tuned!\nSee resources from past talks & presentations here.\nContributors\n\n\n\n\n\n\n\n\n\n\n\nEmily de la Rua\nAbinaya Yogasekaram\n\n\n\n\n\n\n\n\n\nJessica Knizia\nYoshito Koujin\nKorbinian Matthias\n\n\n\n\n\n\n\n\n\nHuan Lu\nHarsha Kalikivayi\nAlex Assuied\n\n\n\n\n\n\n\n\n\nYichen Wang\nYuye Wang"
  },
  {
    "objectID": "quarto/catalog/fda-table_11/index.html",
    "href": "quarto/catalog/fda-table_11/index.html",
    "title": "FDA Table 11",
    "section": "",
    "text": "Table Preview\nSetup\nBuild ARD\nBuild Table\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCode# Load libraries & data -------------------------------------\nlibrary(dplyr)\nlibrary(cards)\nlibrary(gtsummary)\n\nset.seed(1)\nadsl &lt;- random.cdisc.data::cadsl\nadae &lt;- random.cdisc.data::cadae %&gt;%\n  rename(FMQ01SC = SMQ01SC) %&gt;%\n  mutate(\n    AESER = sample(c(\"Y\", \"N\"), size = nrow(.), replace = TRUE),\n    FMQ01NAM = sample(c(\"FMQ1\", \"FMQ2\", \"FMQ3\"), size = nrow(.), replace = TRUE)\n  )\nadae$DCSREAS[is.na(adae$DCSREAS)] &lt;- \"ADVERSE EVENT\"\nadae$FMQ01SC[is.na(adae$FMQ01SC)] &lt;- \"NARROW\"\n\n# Pre-processing --------------------------------------------\ndata &lt;- adae %&gt;%\n  filter(\n    # safety population\n    SAFFL == \"Y\",\n    # narrow FMQ\n    FMQ01SC == \"NARROW\",\n    # discontinuation due to AE\n    DCSREAS == \"ADVERSE EVENT\"\n  )\n\n\n\n\n\nCodeard &lt;- ard_stack_hierarchical(\n  data,\n  variables = c(AEBODSYS, FMQ01NAM),\n  by = TRT01A,\n  denominator = adsl,\n  id = USUBJID\n)\n\nard\n\n\n\n\n{cards} data frame: 225 x 13\n\n\n   group1 group1_level   group2 group2_level variable variable_level   context stat_name stat_label  stat fmt_fn warning error\n1    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      A: Drug X categori…         n          n   134      0              \n2    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      A: Drug X categori…         N          N   400      0              \n3    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      A: Drug X categori…         p          % 0.335   &lt;fn&gt;              \n4    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      B: Place… categori…         n          n   134      0              \n5    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      B: Place… categori…         N          N   400      0              \n6    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      B: Place… categori…         p          % 0.335   &lt;fn&gt;              \n7    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      C: Combi… categori…         n          n   132      0              \n8    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      C: Combi… categori…         N          N   400      0              \n9    &lt;NA&gt;                  &lt;NA&gt;                TRT01A      C: Combi… categori…         p          %  0.33   &lt;fn&gt;              \n10 TRT01A    A: Drug X     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         n          n    53      0              \n11 TRT01A    A: Drug X     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         N          N   134      0              \n12 TRT01A    A: Drug X     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         p          % 0.396   &lt;fn&gt;              \n13 TRT01A    B: Place…     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         n          n    55      0              \n14 TRT01A    B: Place…     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         N          N   134      0              \n15 TRT01A    B: Place…     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         p          %  0.41   &lt;fn&gt;              \n16 TRT01A    C: Combi…     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         n          n    69      0              \n17 TRT01A    C: Combi…     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         N          N   132      0              \n18 TRT01A    C: Combi…     &lt;NA&gt;              AEBODSYS         cl A.1 hierarch…         p          % 0.523   &lt;fn&gt;              \n19 TRT01A    A: Drug X AEBODSYS       cl A.1 FMQ01NAM           FMQ1 hierarch…         n          n    22      0              \n20 TRT01A    A: Drug X AEBODSYS       cl A.1 FMQ01NAM           FMQ1 hierarch…         N          N   134      0              \n21 TRT01A    A: Drug X AEBODSYS       cl A.1 FMQ01NAM           FMQ1 hierarch…         p          % 0.164   &lt;fn&gt;              \n22 TRT01A    B: Place… AEBODSYS       cl A.1 FMQ01NAM           FMQ1 hierarch…         n          n    21      0              \n23 TRT01A    B: Place… AEBODSYS       cl A.1 FMQ01NAM           FMQ1 hierarch…         N          N   134      0              \n24 TRT01A    B: Place… AEBODSYS       cl A.1 FMQ01NAM           FMQ1 hierarch…         p          % 0.157   &lt;fn&gt;              \n25 TRT01A    C: Combi… AEBODSYS       cl A.1 FMQ01NAM           FMQ1 hierarch…         n          n    37      0              \n26 TRT01A    C: Combi… AEBODSYS       cl A.1 FMQ01NAM           FMQ1 hierarch…         N          N   132      0              \n27 TRT01A    C: Combi… AEBODSYS       cl A.1 FMQ01NAM           FMQ1 hierarch…         p          %  0.28   &lt;fn&gt;              \n28 TRT01A    A: Drug X AEBODSYS       cl A.1 FMQ01NAM           FMQ2 hierarch…         n          n    24      0              \n29 TRT01A    A: Drug X AEBODSYS       cl A.1 FMQ01NAM           FMQ2 hierarch…         N          N   134      0              \n30 TRT01A    A: Drug X AEBODSYS       cl A.1 FMQ01NAM           FMQ2 hierarch…         p          % 0.179   &lt;fn&gt;              \n31 TRT01A    B: Place… AEBODSYS       cl A.1 FMQ01NAM           FMQ2 hierarch…         n          n    31      0              \n32 TRT01A    B: Place… AEBODSYS       cl A.1 FMQ01NAM           FMQ2 hierarch…         N          N   134      0              \n33 TRT01A    B: Place… AEBODSYS       cl A.1 FMQ01NAM           FMQ2 hierarch…         p          % 0.231   &lt;fn&gt;              \n34 TRT01A    C: Combi… AEBODSYS       cl A.1 FMQ01NAM           FMQ2 hierarch…         n          n    33      0              \n35 TRT01A    C: Combi… AEBODSYS       cl A.1 FMQ01NAM           FMQ2 hierarch…         N          N   132      0              \n36 TRT01A    C: Combi… AEBODSYS       cl A.1 FMQ01NAM           FMQ2 hierarch…         p          %  0.25   &lt;fn&gt;              \n37 TRT01A    A: Drug X AEBODSYS       cl A.1 FMQ01NAM           FMQ3 hierarch…         n          n    28      0              \n38 TRT01A    A: Drug X AEBODSYS       cl A.1 FMQ01NAM           FMQ3 hierarch…         N          N   134      0              \n39 TRT01A    A: Drug X AEBODSYS       cl A.1 FMQ01NAM           FMQ3 hierarch…         p          % 0.209   &lt;fn&gt;              \n40 TRT01A    B: Place… AEBODSYS       cl A.1 FMQ01NAM           FMQ3 hierarch…         n          n    25      0              \n\n\nℹ 185 more rows\n\n\nℹ Use `print(n = ...)` to see more rows\n\n\n\n\n\nCodetbl &lt;- tbl_hierarchical(\n  data,\n  variables = c(AEBODSYS, FMQ01NAM),\n  by = TRT01A,\n  id = USUBJID,\n  denominator = adsl,\n  overall_row = TRUE,\n  label = list(..ard_hierarchical_overall.. = \"Patients with at least one AE leading to discontinuation\")\n) %&gt;%\n  modify_header(FMQ01NAM = \"FMQ (Narrow)\")\n\ntbl"
  },
  {
    "objectID": "quarto/faq.html",
    "href": "quarto/faq.html",
    "title": "Frequently Asked Questions",
    "section": "",
    "text": "1.  How do I install the cardinal package?\nFor instructions on installing the cardinal package please see the Environment Setup and Package Installation section of the Getting Started page. \n\n\n2.  How can I join this initiative?\nFor information on how to join the cardinal initiative please see the Joining as a Collaborator section of the About page. \n\n\n3.  I copied the example “Table Setup” code for one of the cardinal tables. How can I customize the table?\nFor each table template page, next to the “Table Setup” tab is the “Function Details” tab. This tab contains information about each of the customizable parameters available for the table, and what the default settings for each are. If you require a customization option that is not available for a given table, please file a Feature Request issue on GitHub here. \n\n\n4.  I need a table that isn’t available on the cardinal website. Can I request a table be added?\nThe cardinal team is actively maintaining and adding new table functions to the package. If you would like an FDA safety table that is not listed on the cardinal website, please file a New Table Template issue on GitHub here with the table number and the team will work on adding it to the package. \n\n\n5.  I don’t know the number of the FDA safety table I am interested in. Is there a list of tables by title?\nA list of all available tables by title is available on the Template Catalog page. \n\n\n\nOther Questions - Contact Us\nIf you have questions not listed above please contact us by filing an issue on GitHub here or reaching out to the cardinal team directly via our Slack channel here."
  },
  {
    "objectID": "quarto/index-catalog.html",
    "href": "quarto/index-catalog.html",
    "title": "Template Catalog",
    "section": "",
    "text": "Order By\n       Default\n         \n          Title\n        \n     \n  \n    \n      \n      \n    \n\n\n\n\n\n\n\n\nFDA Table 11\n\n\nPatients with FDA Medical Query (Narrow) Leading to Treatment Discontinuation, Safety Population, Pooled Analyses\n\n\n\ntable\n\n\nFDA\n\n\nsafety\n\n\n\n\n\n\n\n\n\n\n\n\nFDA Table 12\n\n\nPatients With Adverse Events Leading to Treatment Discontinuation by System Organ Class and Preferred Term, Safety Population, Pooled Analyses\n\n\n\ntable\n\n\nFDA\n\n\nsafety\n\n\n\n\n\n\n\n\nNo matching items"
  }
]